An exploratory subgroup analysis revealed that diabetes severity exerts a significant impact on the efficacy of SGLT2 inhibitor-based combination regimens in patients with HFrEF, with more severe diabetes correlating with superior therapeutic responses. The gene discussed is SLC5A2; the disease is diabetes mellitus.